Robert I Blum Cytokinetics Inc (CYTK) insider trading activity

Robert I Blum is President & CEO of CYTOKINETICS INC. Currently has a direct ownership of 397,678 shares of CYTK, which is worth approximately $20.1 Million. The most recent transaction as insider was on Dec 02, 2024, when has been sold 5,000 shares (Common Stock) at a price of $50.76 per share, resulting in proceeds of $253,800. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 398K

0.06% 3M change

9.91% 12M change

Total Value Held $20.1 Million

Robert I Blum Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 02 2024	SELL Open market or private sale	$253,800 $50.76 p/Share	5,000 Reduced 1.24%	397,678 Common Stock
Dec 02 2024	BUY Exercise of conversion of derivative security	$33,350 $6.67 p/Share	5,000 Added 1.23%	402,678 Common Stock
Nov 18 2024	SELL Open market or private sale	$252,750 $50.55 p/Share	5,000 Reduced 1.24%	397,456 Common Stock
Nov 18 2024	BUY Exercise of conversion of derivative security	$33,350 $6.67 p/Share	5,000 Added 1.23%	402,456 Common Stock
Nov 01 2024	SELL Open market or private sale	$258,150 $51.63 p/Share	5,000 Reduced 1.24%	397,456 Common Stock
Nov 01 2024	BUY Exercise of conversion of derivative security	$33,350 $6.67 p/Share	5,000 Added 1.23%	402,456 Common Stock
Oct 09 2024	SELL Open market or private sale	$278,050 $55.61 p/Share	5,000 Reduced 1.24%	397,456 Common Stock
Oct 09 2024	BUY Exercise of conversion of derivative security	$33,350 $6.67 p/Share	5,000 Added 1.23%	402,456 Common Stock
Sep 30 2024	SELL Open market or private sale	$260,700 $52.14 p/Share	5,000 Reduced 1.24%	397,456 Common Stock
Sep 30 2024	BUY Exercise of conversion of derivative security	$33,350 $6.67 p/Share	5,000 Added 1.23%	402,456 Common Stock
Sep 16 2024	SELL Open market or private sale	$279,950 $55.99 p/Share	5,000 Reduced 1.24%	397,456 Common Stock
Sep 16 2024	BUY Exercise of conversion of derivative security	$33,350 $6.67 p/Share	5,000 Added 1.23%	402,456 Common Stock
Sep 03 2024	SELL Open market or private sale	$285,150 $57.03 p/Share	5,000 Reduced 1.24%	397,456 Common Stock
Sep 03 2024	BUY Exercise of conversion of derivative security	$33,350 $6.67 p/Share	5,000 Added 1.23%	402,456 Common Stock
Aug 19 2024	SELL Bona fide gift	-	1,956 Reduced 0.49%	397,456 Common Stock
Aug 12 2024	SELL Open market or private sale	$634,455 $55.17 p/Share	11,500 Reduced 2.8%	399,412 Common Stock
Aug 12 2024	BUY Exercise of conversion of derivative security	$76,705 $6.67 p/Share	11,500 Added 2.72%	410,912 Common Stock
Jul 30 2024	SELL Open market or private sale	$684,135 $59.49 p/Share	11,500 Reduced 2.8%	399,412 Common Stock
Jul 30 2024	BUY Exercise of conversion of derivative security	$76,705 $6.67 p/Share	11,500 Added 2.72%	410,912 Common Stock
Jul 10 2024	SELL Open market or private sale	$624,335 $54.29 p/Share	11,500 Reduced 2.8%	399,412 Common Stock
Jul 10 2024	BUY Exercise of conversion of derivative security	$38,465 $6.67 p/Share	5,767 Added 1.38%	410,912 Common Stock
Jul 01 2024	SELL Open market or private sale	$621,575 $54.05 p/Share	11,500 Reduced 2.76%	405,145 Common Stock
Jun 17 2024	SELL Open market or private sale	$1,183,275 $52.59 p/Share	22,500 Reduced 5.12%	416,645 Common Stock
Jun 04 2024	SELL Open market or private sale	$1,099,125 $48.85 p/Share	22,500 Reduced 4.87%	439,145 Common Stock
Mar 14 2024	BUY Grant, award, or other acquisition	-	61,490 Added 11.76%	461,221 Common Stock

Also insider at

GMDA

Gamida Cell Ltd. Healthcare

Director

RIB

Robert I Blum

President & CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Value

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK

Account